Editorial IV. Do genes influence outcome from anaesthesia?

British Journal of Anaesthesia

Volumn 90, Issue 6, 2003, Pages 725-727

  Sweeney, B P ^a  

^a POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; AMITRIPTYLINE; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DEBRISOQUINE; DIAZEPAM; DICLOFENAC; DROPERIDOL; DYE; HALOPERIDOL; INHALATION ANESTHETIC AGENT; ISONIAZID; METOPROLOL; MORPHINE; OMEPRAZOLE; ONDANSETRON; PRIMAQUINE; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; SPARTEINE; SULFONAMIDE; THIORIDAZINE; TOLBUTAMIDE; TRAMADOL; TROPISETRON; UNINDEXED DRUG; WARFARIN; ANESTHETIC AGENT;

ANESTHESIA; BLADDER CANCER; DIPLOPIA; DNA SEQUENCE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EDITORIAL; GENE DELETION; GENE MUTATION; GENETIC POLYMORPHISM; HEMOLYSIS; HUMAN; LUPUS ERYTHEMATOSUS; MOLECULAR GENETICS; NAUSEA; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ACETYLATION; BIOTRANSFORMATION; GENE EXPRESSION PROFILING; GENETICS; METHYLATION; NOTE;

ACETYLATION; ANESTHETICS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; GENE EXPRESSION PROFILING; HUMANS; METHYLATION;

EID: 0038341988     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeg103     Document Type: Editorial

References (30)

1. Nebert DW, Russell DW. Clinical importance of the cytochromes. P450. Lancet 2002; 360: 1155-62
2. Sweeney BP. Why does smoking protect against PONV? Br J Anaesth 2002; 89: 1-4
3. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1955; 29: 129-209
4. Marth GT, Korf I, Yandell MD, et al. A general approach to single nucleotide polymorphism discovery. Nature Genet 1999; 23: 452-6
5. Carsen PE, Flanagan CL, Iokes CE. Enzymatic deficiency in promaquine-sensitive erythrocytes. Science 1956; 124: 484-5
6. Hughes HB, Biehl JP, Jones AP. Metabolism of isoniazide in man as related to the occurrence of peripheral neuritis. Am Rev Tuberculosis 1954; 70: 266-73
7. Spielberg SP. N-Acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996; 24: 509-19
8. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharm 1979; 16: 183-7
9. Mahgoub A, Idle JR, Dring LG, Lancater R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-6
10. Pelkonen O, Maenpa J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998; 28: 1203-53
11. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolisers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991; 48: 943-50
12. Broly F, Gaedigk A, Heim M, Eichelbaum M, Kroemer HK. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10: 545-58
13. Poulsen L, Brosen K, Arendt-Nielsen L. Codeine and morphine in extensive and poor metabolisers of sparteine: pharmacokinetics, analgesic effects and side efects. Eur J Clin Pharmacol 1996; 51: 289-95
14. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996; 278: 1165-74
15. Yue Q, Alm C, Svensson J, Sawe J. Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Ther Drug Monit 1997; 19: 539-42
16. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636-44
17. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000; 25: 197-220
18. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalised medicine. AAPS Pharm Sci 2000; 2: 30-7
19. Aithal GP, Day CP, Leathart JBS. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511-18
20. Apfel CC, Kranke P, Katz MH, et al. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomised controlled trial of factorial design. Br J Anaesth 2002; 88: 659-68
21. Kharasch ED, Thummel KE. Identification of cytochrome P450 2EI as the predominant enzyme catalysing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 1993; 79: 795-807
22. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P4502EI gene. J Biochem 1991; 110: 559-65
23. Reavley CM, Cherkas L, Spector TD, MacGregor AJ. Genetic factors contribute to the risk of postoperative nausea and vomiting, results of a twin study. Br J Anaesth 1999: 82 (suppl. 1): 1-2
24. Ingelman-Sundberg M, Johansson I, Yin H, et al. Ethanol inducible cytochrome P4502EI: genetic polymorphism, regulation and possible role in the aetiology of alcohol-induced liver disease. Alcohol 1993; 10: 447-52
25. Eliasson E, Gardner I, Hume-Smith H, de Waziers I, Beaune P, Kenna JG. Interindividual variability in P-450 dependent generation of neoantigens in halothane hepatitis. Chem Biol Interact 1998; 116: 123-41
26. Chimbira W, Sweeney BP. The effect of smoking on postoperative nausea and vomiting. Anaesthesia 2000; 55: 540-5
27. Bond C, LaForge KS, Tian M. Single nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity. Possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95: 9608-13
28. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15: 410-7
29. Stueber F, Hoeft A. The influence of genomics on outcome after cardiovascular surgery. Curr Opin Anaesth 2002; 15: 3-8
30. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Toxicol 2001; 41: 101-21